JGC
ZVRA icon

J. Goldman & Co’s Zevra Therapeutics ZVRA Stock Holding History

J. Goldman & Co’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-97,500
Closed -$813K – 674
2024
Q4 		$813K Buy
97,500
+94,100
+2,768% +$803K 0.02% 342
2024
Q3 		$23.6K Buy
+3,400
New +$23.1K ﹤0.01% 437

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

J. Goldman & Co's ZVRA Position: Q2 2026 in Review

J. Goldman & Co held its Zevra Therapeutics (ZVRA) position steady in Q2 2026 at 13,497 shares worth $194K. The position accounts for 0.01% of the portfolio, ranked #641.

J. Goldman & Co first reported a position in ZVRA in Q4 2018 and has held it in 9 quarters since. The position peaked at $7.3M in Q4 2024. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • J. Goldman & Co held 13,497 shares of Zevra Therapeutics worth $194K as of Q2 2026.
  • J. Goldman & Co left its Zevra Therapeutics share count unchanged in Q2 2026.
  • Zevra Therapeutics made up 0.01% of J. Goldman & Co's portfolio in Q2 2026, its #641 holding.
  • J. Goldman & Co first reported a position in Zevra Therapeutics in Q4 2018 and has held it in 9 quarters since.
  • J. Goldman & Co's Zevra Therapeutics position peaked at $7.3M in Q4 2024.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.